ovarian-cancer

Documents about ovarian-cancer

• The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)#897319ClinicalTrials.gov
• Analysis of the expression of human tumor antigens in ovarian cancer tissues#129201PMC Full-Text (OAI)
• Leveraging AI chatbots in supporting breast and ovarian cancer patients: A scoping review.#182489NCBI PubMed Central
• PARylation-centric crosstalk: orchestrating immune evasion and multidrug resistance in ovarian cancer.#199151NCBI PubMed Central
• A role for PAX8 in the tumorigenic phenotype of ovarian cancer cells#254381IRIS
• Multi-armored mesenchymal stem cells potentiate antitumor immunity to combat ovarian cancer.#285133NCBI PubMed Central
• Predictive and Prognostic Value of Microsatellite Instability in Gynecologic Cancer (Endometrial and Ovarian)#322449HAL (France)
• Metronomic Chemotherapy in Ovarian Cancer: Current Scenario and AI-Integrated Future Strategies.#362203NCBI PubMed Central
• Corrigendum to ‘Endometriosis and ovarian cancer risk’ [Gynecologic Oncology 209C (2026) 88–98]#374403HAL (France)
• Ovarian Cancer Diagnosis and Chemoresistance Prediction Model Based on cfRNA Molecular Signature.#380724NCBI PubMed Central
• Treatment-related Cognitive Impairment, Neurovascular Coupling, and Iron Levels in Women with Ovarian Cancer#478024bioRxiv / medRxiv
• Ovarian Tissue Cryopreservation and Subsequent Auto-Transplantation for Female Cancer Patients#891391ClinicalTrials.gov
• An Open Label Extension Study of the Efficacy of MORAb-003#908029ClinicalTrials.gov
• Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid Tumors#860896ClinicalTrials.gov
• Predicting tumor response and outcome of second-look surgery with 18F-FDG PET/CT: insights from the GINECO CHIVA phase II trial of neoadjuvant chemotherapy plus nintedanib in stage IIIc-IV FIGO ovarian cancer#665118HAL (France)
• Prevention and Treatment of CINV Caused by TC Regimen in Gynecological Malignant Tumor Patients#805631ClinicalTrials.gov
• Imaging Study on Halcyon 4.0 System for Patients Receiving Radiation Therapy#806851ClinicalTrials.gov
• A Study of PY314 in Subjects With Advanced Solid Tumors#905310ClinicalTrials.gov
• COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies#838735ClinicalTrials.gov
• A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies#849810ClinicalTrials.gov
• BOLSTER: Building Out Lifelines for Safety, Trust, Empowerment and Renewal#887772ClinicalTrials.gov
• Food Supplements Based on Nettle and Peppermint to Control Signs and Symptoms Induced by Cancer Therapies#913958ClinicalTrials.gov
• Best original research presented at the 27th European Congress on Gynaecological Oncology: best of ESGO 2026#472091IRIS
• AOH1996 for the Treatment of Refractory Solid Tumors#872103ClinicalTrials.gov
• Decision-making Regarding Prophylactic Mastectomy and Oophorectomy in Women Seeking Genetic Counseling and Testing for BRCA1/2 Mutations#910103ClinicalTrials.gov
• Paclitaxel Plus Gemcitabine in Treating Patients With Refractory Metastatic Germ Cell Tumors#874659ClinicalTrials.gov
• Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer#905980ClinicalTrials.gov
• Context-dependent reconfiguration and spatial reorganisation of the miR-199a-5p/XIAP axis in high-grade serous ovarian cancer#160426bioRxiv / medRxiv
• Ovarian cancer tumor immune profiles associated with intrauterine device and oral contraceptive use#631996Springer Nature OA
• Phase I Trial of VS-6766 Alone and in Combination With Everolimus#837659ClinicalTrials.gov
• Enoxaparin Thromboprophylaxis in Cancer Patients With Elevated Tissue Factor Bearing Microparticles#870302ClinicalTrials.gov
• NTX-301 Monotherapy in Advanced Solid Tumours and in Combination With Platinum-based Chemotherapy in Advanced Ovarian & Bladder Cancer and in Combination With Temozolomide in High-grade Glioma#826309ClinicalTrials.gov
• A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies#901932ClinicalTrials.gov
• Development and evaluation of methodologies for analysis of CTC and ctDNA in patients with ovarian carcinoma#459134Research Online
• Study of ADCT-301 in Patients With Selected Advanced Solid Tumors#814039ClinicalTrials.gov
• A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients#872283ClinicalTrials.gov
• Ancillary Study GOG 158: Survival Analysis Based on Reclassification to a Two-Tier Grading System#842387ClinicalTrials.gov
• A Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors#858358ClinicalTrials.gov
• Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors#839548ClinicalTrials.gov
• A Study of ABBV-428, an Immunotherapy, in Subjects With Advanced Solid Tumors#875330ClinicalTrials.gov
• Feasibility of a New Technology for Isolating Circulating Tumour Cells#884624ClinicalTrials.gov
• Lynne Cohen Consortium Project: Multi-Center Database/Registry#892380ClinicalTrials.gov
• SMMART Adaptive Clinical Treatment (ACT) Trial#805987ClinicalTrials.gov
• 18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors#881267ClinicalTrials.gov
• 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)#841847ClinicalTrials.gov
• The incidence and risk factors of sepsis following ovarian cancer surgery: A retrospective Nationwide Inpatient Sample database study#385430PLOS
• Testing a Decision Aid to Help Patients with Ovarian Cancer Choose between Two Ways to Get Chemotherapy#2246NCBI Bookshelf
• Nonadherence to guidelines for genetic testing in families with ovarian cancer shows racial bias.#30603NCBI PubMed Central
• Multi-Omic Profiling Reveals Antibody-Drug Conjugate Targetability in Ovarian Cancer#135513Unpaywall
• Efficacy of chemotherapy after progression during or following PARPi exposure in ovarian cancer#166555HAL (France)